| 产品详情 |
| Edit |   |
|---|
| Product Name | Veliparib |
|---|
| Description | Purity ≥99% (HPLC, TLC). ABT-888 is a potent, orally bioavailable PARP-1/-2 inhibitor shown to potentiate DNA damaging agents. The ability to potentiate temozolomide (TMZ) and develop a biological marker for PARP inhibition was evaluated in vivo. Veliparib, also known as ABT-888, is a potent inhibitor of PARP-1 and PARP-2, with Ki values of 5.2 nM and 2.9 nM, respectively. It was demonstrated to have good oral bioavailability, to cross the blood-brain barrier well, to have modest antitumor activity alone, and to potentiate temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. Donawho C.K., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13: 2728-2737 (2007). A phase 1 clinical study demonstrated that the combination of veliparib with metronomic cyclophosphamide was well tolerated and showed promising activity in a subset of patients wi |
|---|
| Size | 10mg, 25mg, 50mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide; A 861695; ABT 888 |
|---|
| Gene, Accession, CAS # | ABT-888 |
|---|
| Catalog # | 1028 |
|---|
| Price | |
|---|
| Order / More Info | Veliparib from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|